These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30208863)

  • 1. Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
    Fernandes GS; Girardi DM; Bernardes JPG; Fonseca FP; Fregnani ER
    BMC Cancer; 2018 Sep; 18(1):887. PubMed ID: 30208863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunohistochemical and genetic study of BRAF
    Seki-Soda M; Sano T; Ito K; Yokoo S; Oyama T
    Pathol Int; 2020 Apr; 70(4):224-230. PubMed ID: 31930640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
    Yan XC; Sun LS; Dong ZW; You Z; Dong Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent response to vemurafenib in metastatic ameloblastoma with BRAF mutation: a case report.
    Broudic-Guibert M; Blay JY; Vazquez L; Evrard A; Karanian M; Taïeb S; Hoog-Labouret N; Oukhatar CMA; Boustany-Grenier R; Arnaud A
    J Med Case Rep; 2019 Jul; 13(1):245. PubMed ID: 31340860
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Mutational Profile of Unicystic Ameloblastoma.
    Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
    J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
    Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
    J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
    You Z; Liu SP; Du J; Wu YH; Zhang SZ
    J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
    Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G
    J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
    Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
    Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
    Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F
    Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress towards personalized medicine for ameloblastoma.
    Gomes CC; Diniz MG; Gomez RS
    J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
    Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
    Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF V600E mutation mediates invasive and growth features in ameloblastoma.
    Zhang CX; Zhang LZ; Lin H; Man QW; Liu B
    Oral Dis; 2024 Oct; 30(7):4426-4439. PubMed ID: 38424736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for advanced ameloblastoma in the era of precision medicine: A brief review.
    Oh KY
    Oral Oncol; 2023 Nov; 146():106585. PubMed ID: 37816291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical analysis of BRAF V600E mutation in ameloblastomas.
    do Canto AM; da Silva Marcelino BMR; Schussel JL; Wastner BF; Sassi LM; Corrêa L; de Freitas RR; Hasséus B; Kjeller G; Junior CAL; Braz-Silva PH
    Clin Oral Investig; 2019 Feb; 23(2):779-784. PubMed ID: 29855709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resolution of PTHrP-Mediated Hypercalcemia Following Treatment with Dual BRAF/MEK Inhibition for BRAFV600E-Positive Metastatic Ameloblastoma.
    Corbett K; Ruether D; Seiden-Long I; Kline G
    Calcif Tissue Int; 2024 Apr; 114(4):444-449. PubMed ID: 38252285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Study of
    Kokubun K; Yamamoto K; Akashi Y; Chujo T; Nakajima K; Matsuzaka K
    Int J Surg Pathol; 2022 Jun; 30(4):378-384. PubMed ID: 34994576
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.